149 related articles for article (PubMed ID: 33511314)
1. Antibody-activated trans-endothelial delivery of mesoporous organosilica nanomedicine augments tumor extravasation and anti-cancer immunotherapy.
Huang T; Li S; Fang J; Li F; Tu S
Bioact Mater; 2021 Jul; 6(7):2158-2172. PubMed ID: 33511314
[TBL] [Abstract][Full Text] [Related]
2. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
[TBL] [Abstract][Full Text] [Related]
3. Transcytosis-enabled active extravasation of tumor nanomedicine.
Zhou Q; Li J; Xiang J; Shao S; Zhou Z; Tang J; Shen Y
Adv Drug Deliv Rev; 2022 Oct; 189():114480. PubMed ID: 35952830
[TBL] [Abstract][Full Text] [Related]
4. Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses.
Liu X; Feng Z; Wang C; Su Q; Song H; Zhang C; Huang P; Liang XJ; Dong A; Kong D; Wang W
Biomaterials; 2020 Feb; 230():119649. PubMed ID: 31791843
[TBL] [Abstract][Full Text] [Related]
5. A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma.
Kim SS; Harford JB; Moghe M; Slaughter T; Doherty C; Chang EH
Int J Cancer; 2019 Nov; 145(9):2535-2546. PubMed ID: 31241175
[TBL] [Abstract][Full Text] [Related]
6. Mesoporous silica/organosilica nanoparticles for cancer immunotherapy.
Theivendran S; Lazarev S; Yu C
Exploration (Beijing); 2023 Jun; 3(3):20220086. PubMed ID: 37933387
[TBL] [Abstract][Full Text] [Related]
7. Computer-assisted engineering of programmed drug releasing multilayer nanomedicine via indomethacin-mediated ternary complex for therapy against a multidrug resistant tumor.
Che L; Liu Z; Wang D; Xu C; Zhang C; Meng J; Zheng J; Yuan H; Zhao G; Zhou X
Acta Biomater; 2019 Oct; 97():461-473. PubMed ID: 31344512
[TBL] [Abstract][Full Text] [Related]
8. Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy.
Chen Q; Xu L; Chen J; Yang Z; Liang C; Yang Y; Liu Z
Biomaterials; 2017 Dec; 148():69-80. PubMed ID: 28968536
[TBL] [Abstract][Full Text] [Related]
9. Bioinspired and Biomimetic Nanomedicines.
Chen Z; Wang Z; Gu Z
Acc Chem Res; 2019 May; 52(5):1255-1264. PubMed ID: 30977635
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicine-Based Immunotherapy for the Treatment of Cancer Metastasis.
Zhang P; Zhai Y; Cai Y; Zhao Y; Li Y
Adv Mater; 2019 Dec; 31(49):e1904156. PubMed ID: 31566275
[TBL] [Abstract][Full Text] [Related]
11. Tumor-Targeted Drug and CpG Delivery System for Phototherapy and Docetaxel-Enhanced Immunotherapy with Polarization toward M1-Type Macrophages on Triple Negative Breast Cancers.
Chen L; Zhou L; Wang C; Han Y; Lu Y; Liu J; Hu X; Yao T; Lin Y; Liang S; Shi S; Dong C
Adv Mater; 2019 Dec; 31(52):e1904997. PubMed ID: 31721331
[TBL] [Abstract][Full Text] [Related]
12. Dual Intratumoral Redox/Enzyme-Responsive NO-Releasing Nanomedicine for the Specific, High-Efficacy, and Low-Toxic Cancer Therapy.
Jia X; Zhang Y; Zou Y; Wang Y; Niu D; He Q; Huang Z; Zhu W; Tian H; Shi J; Li Y
Adv Mater; 2018 Jul; 30(30):e1704490. PubMed ID: 29889325
[TBL] [Abstract][Full Text] [Related]
13. Transcytosis of Nanomedicine for Tumor Penetration.
Liu Y; Huo Y; Yao L; Xu Y; Meng F; Li H; Sun K; Zhou G; Kohane DS; Tao K
Nano Lett; 2019 Nov; 19(11):8010-8020. PubMed ID: 31639306
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory nanomedicine for colorectal cancer treatment: a landscape to be explored?
Silveira MJ; Castro F; Oliveira MJ; Sarmento B
Biomater Sci; 2021 May; 9(9):3228-3243. PubMed ID: 33949441
[TBL] [Abstract][Full Text] [Related]
15. Seed- and Soil-Dependent Differences in Murine Breast Tumor Microenvironments Dictate Anti-PD-L1 IgG Delivery and Therapeutic Efficacy.
Liu YT; Goel S; Kai M; Moran Guerrero JA; Nguyen T; Mai J; Shen H; Ziemys A; Yokoi K
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33920216
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
17. Glucose transporter 1-mediated vascular translocation of nanomedicines enhances accumulation and efficacy in solid tumors.
Suzuki K; Miura Y; Mochida Y; Miyazaki T; Toh K; Anraku Y; Melo V; Liu X; Ishii T; Nagano O; Saya H; Cabral H; Kataoka K
J Control Release; 2019 May; 301():28-41. PubMed ID: 30844476
[TBL] [Abstract][Full Text] [Related]
18. Ultrasmall mesoporous organosilica nanoparticles: Morphology modulations and redox-responsive biodegradability for tumor-specific drug delivery.
Yu L; Chen Y; Lin H; Du W; Chen H; Shi J
Biomaterials; 2018 Apr; 161():292-305. PubMed ID: 29427925
[TBL] [Abstract][Full Text] [Related]
19. Biomimetic Redox-Responsive Mesoporous Organosilica Nanoparticles Enhance Cisplatin-Based Chemotherapy.
Chen F; Zhang F; Wang Y; Peng J; Cao L; Mei Q; Ge M; Li L; Chen M; Dong WF; Chang Z
Front Bioeng Biotechnol; 2022; 10():860949. PubMed ID: 35372319
[TBL] [Abstract][Full Text] [Related]
20. Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy.
Yang P; Lu C; Qin W; Chen M; Quan G; Liu H; Wang L; Bai X; Pan X; Wu C
Acta Biomater; 2020 Mar; 104():147-157. PubMed ID: 31904558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
